Drug and Therapeutics Bulletin 1995;33:21-22; doi:10.1136/dtb.1995.33321
Copyright © 1995 by the BMJ Publishing Group Ltd.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation

Once-a-day topical corticosteroids

Relevant BNF section: 13.4

Topical corticosteroids have transformed the management of inflammatory skin diseases since their introduction in the 1950s. Hydrocortisone was the first to be marketed, and since then steroids with greater topical activity have been synthesised. Two products, mometasone furoate ({blacktriangledown}Elocon - Schering-Plough) and fluticasone propionate ({blacktriangledown}Cutivate - Glaxo), both of which are classed as "potent" steroids,1,2 are now marketed in the UK for once-daily application. Their manufacturers claim that they are as effective when used in this way as other potent steroids applied more frequently.






About DTB - Privacy policy - Terms and conditions relating to subscriptions purchased online - Web site terms and conditions - Feedback

© 1995 BMJ Publishing Group Ltd.